Ad Header



The Pulse of the Pharmaceutical Industry

Roche test showed Tecentriq helped vs bladder cancer

Written by: | | Dated: Monday, August 5th, 2019


Roche says test showed Tecentriq helped vs bladder cancer


ZURICH (Reuters) – Roche Holding said its Tecentriq drug combined with platinum-based chemotherapy reduced the risk of the disease worsening or death in patients with advanced bladder cancer, the Swiss pharma company said on Monday.

Tecentriq was the first cancer immunotherapy approved in bladder cancer, with Roche now evaluating the treatment in combination with other medicines for early and advanced forms of the disease.

The Phase III study met its targets of preventing the condition worsening, when compared with chemotherapy alone. Roche said it would share the data with the U.S. Food and Drug Administration and the European Medicines Agency.


Reporting by John Revill, editing by Riham Alkousaa


Reuters source:

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom